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ABSTRACT

OBJECTIVE: The objective of this selective EBM review is to determine whether or not
botulinum toxin injection is effective in reducing pain in patients diagnosed with plantar fasciitis.
STUDY DESIGN: Review of three randomized controlled trials (RCTs) comparing the efficacy
of botulinum toxin injections versus corticosteroid injections for improving pain and dysfunction
in those diagnosed with plantar fasciitis.
DATA SOURCES: All articles were presented in English and were taken from peer reviewed
sources using PubMed. All articles were published from 2012-2017.
OUTCOMES: Outcomes of investigation measured are pain score measured using the VASvisual analog scale and Foot Health Status Questionnaire.
RESULTS: Ahmad et al. found significant improvement in subjective pain scores following the
administration of botulinum toxin injected into the plantar fascia after a period of six months and
one year when compared to a placebo of saline. Diaz-Llopis et al. found significant improvement
in subjective pain scores following the administration of botulinum toxin injected into the plantar
fascia after a period of six months when compared to a corticosteroid. Elizondo-Rodriguez et al.
found significant improvement in subjective pain scores following the administration of
botulinum toxin injected into the plantar fascia after a period of six months when compared to a
corticosteroid.
CONCLUSIONS: These three studies showed a significant improvement in subjective pain
scores after a minimum period of six months and formalized physical therapy program. The
efficacy of botulinum toxin in the treatment of plantar fasciitis is apparent but more research is
needed with larger sample sizes to solidify the hypothesis that botulinum toxin injection should
be an accepted treatment option across the industry.
KEYWORDS: plantar fasciitis, botulinum, and injection

Fry, Botox for Plantar Fasciits 3

INTRODUCTION:
Plantar fasciitis is the most frequent cause of chronic heel pain which generally presents
in patients who are 40 years of age or older, overweight, sedentary, or engage in intense physical
activity. The plantar fascia functions to prevent foot collapse because of its tensile strength and
anatomic orientation. The inflammation of this structure leads to the symptoms experienced by
approximately 10% of the population.1 Plantar fasciitis is a clinical condition that presents as
sharp pain in the heel that spans from the medial border of the plantar fascia to its insertion at the
medial tuberosity of the calcaneus. Pain is provoked with loading and with the initial few steps
following periods of inactivity. These symptoms are elicited by actions such as rising from sleep
in the morning and toward the end of day at rest. Development of plantar fasciitis is thought to
be caused by biomechanical defects such as hyper-pronation. Hyper-pronation contributes to the
excessive mobility of the foot which can increase stress on the plantar fascia.
Treatment options for plantar fasciitis include operative and non-operative. Operative
options include plantar fascial debridement and release.2 Non-operative options include physical
therapy, injections, and insoles.1 Injection options were initially restricted to corticosteroid
injection which have only limited effectiveness but was the mainstay of treatment due to a lack
of alternatives.3 An alternative has been proposed for the management of plantar fasciitis which
is botulinum toxin injections.3,4,5 Botulinum toxin blocks presynaptic acetylcholine reuptake,
produces weakness of the muscles related to the plantar fascia and reduces the tension which
improves the pain.5 This is similar to botulinum toxin’s action in the treatment of myofascial
pain disorders.5 It also has an analgesic action due to the inhibition of the release of
neurotransmitters involved in nociceptive neural pathways (glutamate, substance P and
calcitonin-gene related peptide).4 Many practitioners have utilized this therapeutic measure after

Fry, Botox for Plantar Fasciits 4

all other options have been exhausted in the progression of the patient’s case. Therefore, these
patients may have responded favorably to this therapeutic injection without having to endure the
other more drastic and painful measures if botulinum toxin was an accepted first line therapy.
OBJECTIVE:
The objective of this selective EBM review is to determine whether or not botulinum
toxin injection is effective in reducing pain in patients diagnosed with plantar fasciitis.
METHODS:
Three randomized controlled trials were chosen for review. The patient population
selected for review were ambulatory patients above the age of 18 years old with a diagnosis of
plantar fasciitis. Interventions utilized included injecting botulinum toxin at 100 units into the
inflamed plantar fascia. Depending on the study, subjects either received the botulinum toxin
injection, a corticosteroid injection or a saline placebo. The outcomes were patient oriented and
focused on subjective pain scores utilizing the VAS-visual analog scale or the foot health status
questionnaire depending on the study.
The PubMed database was utilized to select the studies. Keywords to search were
“plantar”, “fasciitis”, “botulinum”, and “injection.” The three studies selected were published in
peer reviewed journals from 2012-2017 and all were written in English. The inclusion and
exclusion criteria for all three studies were similar. The inclusion criteria was randomized,
controlled, blinded study that evaluated subjects aged >18 years of age, ambulatory, and
diagnosed with plantar fasciitis. The exclusion criteria was patients diagnosed with other
pathology than plantar fasciitis for heel pain. Detailed inclusion, exclusion criteria, and other
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individual study characteristics are provided in Table 1. The statistics reported in the studies and
utilized for the review were mean changes from baseline and p-values.
Table 1: Demographics & Characteristics of Ahmad et al., Diaz-Llopis et al., & ElizondoRodriguez et al.
Study

Type

Inclusion Criteria

Exclusion Criteria

RCT

# Pts Age
(yrs)
50
31-69

Ahmad
(2017)

W/D

Interventions

Acute or chronic
plantar fasciitis
who had no
improvement in
symptoms after a
minimum of 6
weeks of nonoperative
treatment

Prior botulinum toxin 0
injections for plantar
fasciitis

A 1 mL injection of
100U of IBTA vs. a
saline placebo
injection

Diaz
(2012)

RCT

56

SD
51-56

Clinical diagnosis
of plantar fasciitis
based on
presence of heel
pain during first
steps after a
period of rest or
pain exacerbated
by walking or by
standing for
many hours

Those with heel pain
due to other causes
or painful disorders
of the foot that could
coexist with plantar
fasciitis.

0

100U of botulinum
toxin type A was
diluted in 1 mL of
normal saline and
70U were injected vs.
2 mL of
betamethasone
6mg/mL plus 0.5 mL
of 1% mepivacaine

Rodriguez
(2013)

Double
Blind
RCT

40

29-54

Skeletally mature
with heel pain at
the insertion of
the plantar fascia
or anteromedial
tuberosity of the
calcaneus; failure
of conservative
treatment for 3
months, which
consisted of pads
in ordinary shoe
and NSAIDs

Previous injections,
4
associated
pathologies or a
history of infection at
the injection site in
the previous 3
months

100U of BTX-A was
injected into each
muscle belly vs. a
combination of 2%
lidocaine and 8mg of
dexamethasone
injected into medial
aspect of the plantar
surface
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OUTCOMES MEASURED:
This review examined subjective pain scores after therapeutic injections were
administered. Patients were evaluated over 6 month periods to assess response to the injections.
To measure the subjective pain responses, two subjective scoring evaluators were utilized; the
VAS-visual analog scale and the Foot Health Questionnaire. These subjective scoring systems
evaluated the patients’ response to the injections by their pain with various modalities following
a designated time period.
RESULTS:
Ahmad et. al., conducted a randomized, double blinded, placebo controlled trial
comparing 50 subjects who presented with a diagnosis of plantar fasciitis. The authors reported a
mean age of 51.3 in the placebo group and 48.6 in the botulinum toxin group respectively.2 This
study included subjects with either acute or chronic plantar fasciitis who had no improvement in
symptoms after a minimum of 6 weeks of non-operative treatment. This study excluded any
subjects who had prior botulinum toxin for plantar fasciitis. This study examined the subjects’
response to either a 1mL injection of 100U of IBTA vs. a saline placebo injection after 6 &12
months.2 The principal investigator, the neurologist giving the injections, and all study patients
were blinded from what substance was injected.2 Only the independent observer knew which
study patients received IBTA and which patients received placebo.2 There were 0% loss to
follow up at the conclusion of the research. The researchers used continuous data, which is
provided in Table 2. The results of this study show that IBTA provided significant relief of pain
due to plantar fasciitis compared with normal saline injection. Using a mean change from
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baseline, examiners found that there were significant changes from baseline when comparing
IBTA injection to saline placebo using a P< 0.05 as being statistically significant.
Table 2: Post-injection Demographics between the Placebo and IBTA Groups.2
Post injection
Demographics
VAS at 6 months,
mean (range)

Placebo

IBTA

P-Value

7.9/10 (6-9)

3.6/10 (0-8)

0.01

Diaz-Llopis et. al., conducted a randomized, placebo controlled trial comparing 56
subjects who presented with a diagnosis of plantar fasciitis. The authors reported a mean age of
51.5 in the BTX-A group and 56.4 in the CS group respectively.5 This study included subjects
with a clinical diagnosis of plantar fasciitis based on presence of heel pain during first steps after
a period of rest or pain exacerbated by walking or by standing for many hours.5 This study
excluded those with heel pain due to other causes or painful disorders of the foot that could
coexist with plantar fasciitis.5 This study examined the subjects’ response after 6 months
following injection of either; 100U of botulinum toxin type A (BTX-A) which was diluted with
1mL of normal saline and 70U were injected or 2mL of betamethasone 6mg/mL plus 0.5 mL of
1% mepivacaine (CS).5 Patients did not know which treatment they were to receive and the
medication was prepared out of sight of the specialist performing the injection.5 However, they
could not describe this as a true double-blind study as the injection volumes of the two
treatments were different and the specialist could therefore guess which one was being given.5
There were 0% loss to follow up at the conclusion of the research. The researchers used
continuous data, which is provided in Table 3. The results of this study show that BTX-A
provided significant relief of pain due to plantar fasciitis compared with the corticosteroid
injection. Using a mean change from baseline, examiners found that there were significant
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changes from baseline when comparing BTX-A injection to CS injection using a P< 0.05 as
being statistically significant.
Table 3: Difference in foot health status questionnaire scores between baseline, 1 month and 6
months after treatment with BTX-A.3
FHSQ-pain

At 1 month

Mean (SD)

63.30 (21.90)

Change
(FHSQ 1
monthbaseline)
34.24 (21.10)

At 6 month

75.71 (24.14)

Change
(FHSQ 6
month- 1
month)
19.10 (24.76)

P-value

P<0.001

Elizondo-Rodriguez et.al., conducted a randomized, double blinded, placebo controlled
trial comparing 40 subjects who presented with a diagnosis of plantar fasciitis. The authors
reported a mean age of 41.6 in the BTX-A group and 44.5 in the CS group respectively.6 This
study included subjects who were skeletally mature with heel pain at the insertion of the plantar
fascia or anteromedial tuberosity of the calcaneus; failure of conservative treatment for 3 months,
which consisted of pads in ordinary shoe and NSAIDs.5 This study excluded those who received
previous injections, associated pathologies or a history of infection at the injection site in the
previous 3 months.5 This study examined the subjects’ response to 100U of BTX-A which was
injected into each muscle belly vs. a combination of 2% lidocaine and 8mg of dexamethasone
(CS) injected into the medial aspect of the plantar surface after 6 months.5 The patients were
randomly divided into 2 groups using a randomizing software program. The evaluation of the
subjects’ response to treatment were made by a blinded investigator who was unaware of the
patient group assignments.5 There were 10% loss to follow up at the conclusion of the research.
The researchers used continuous data, which is provided in Table 4. The results of this study
show that BTX-A provided significant relief of pain due to plantar fasciitis compared with the
corticosteroid injection. Using a mean change from baseline, examiners found that there were
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significant changes from baseline when comparing BTX-A injection to CS injection using a P<
0.05 as being statistically significant.
Table 4: Comparison between Groups Evaluating Visual Analogue Scale (VAS).5
Group A
(BTX-A):
Value
7.1
1.1

Initial
Final

Group A
Group B
(BTX-A): SD (CS): Value

Group B
(CS): SD

P-value

1.75
1.50

1.32
1.15

Ns
0.0005

7.7
3.8

Infections and other risks are associated with the interventions employed in these studies.
Cases of rupture of the plantar fascia have been reported after corticosteroid injection.3,7
However, none of the reviewed studies reported any drug related adverse effects or safety
concerns.
DISCUSSION:
This evidence based systematic review focused on the use of botulinum toxin injections
being utilized to treat the symptoms of plantar fasciitis in those over the age of 18 years old. The
etiology and pathogenesis of plantar fasciitis are still not fully understood.6 Although some
authors consider the disorder to be the result of excessive tension in the fascia, producing
microscopic tears which lead to a subsequent inflammatory repair process, many others have
demonstrated degenerative changes, though without finding signs of inflammation.6 Entrapment
of the first branch of the lateral plantar nerve has also been cited as a possible cause of heel pain.6
Regardless if a consensus regarding the pathogenesis of this disorder has not been reached
throughout the industry, the fact still remains that patients seek treatment for their symptoms and
require a therapy that will alleviate their discomfort even if it may be temporary. This uncertainty
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in having a widely accepted therapeutic intervention for plantar fasciitis mandates the need for
further research into this topic.
Throughout researching this topic, there were a few study limitations that could have
impacted this review. A limitation that was apparent early on was the fact that many plantar
fasciitis studies focused on surgical management. This significant narrowed the available studies
to choose from. Another limitation was the fact that many of the studies had a small sample
sizes. Therefore, finding studies that met the minimum requirements of statistical significance
became challenging but was not overall impossible. If larger sample sizes could be utilized, the
statistics would provide more evidence for the efficacy of the proposed treatment because the
results could signify the true difference in efficacy and minimize the impact of confounding
variables.
CONCLUSION:
The evidence presented in this systematic review shows that injections of botulinum toxin
have a positive effect on subjective pain scores after a period of six months. Within this period of
six months, patients were prescribed a formalized physical therapy program for a minimum of
six weeks. Patients are encouraged to continue the modalities taught in these six week programs
after the conclusion of the six weeks. The program involved active and passive stretching of the
plantar fascia, great and lesser toe flexors, and Achilles tendons with and without resistance.2
Other modalities that are regularly prescribed for physical therapy include ultrasound, massage,
moist heat and cryotherapy.2 The physical therapy programs were employed regardless of the
intervention utilized in the study. Therefore, physical therapy should always be integrated into
the treatment plan to maximize the recovery of the patient’s symptoms.
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Only a few studies exist showing the therapeutic benefit of botulinum toxin injections for
plantar fasciitis exist. Therefore, the efficacy of botulinum toxin in the treatment of plantar
fasciitis is apparent but more research is needed with larger sample sizes to solidify the
hypothesis that botulinum toxin injection should be an accepted treatment option across the
industry.
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